| HOME >> BIOLOGY >> TECHNOLOGY |
PhenoSense(R) Integrase Now Enables Clinicians to Monitor Activity of New
Class of Potent Antiretroviral Drugs
SOUTH SAN FRANCISCO, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced the launch of its PhenoSense(R) Integrase assay, built on Monogram's proprietary technology platform, PhenoSense(R). The assay directly measures the susceptibility of HIV to a new and potent class of integrase inhibitor drugs that blocks viral replication by preventing viral genes from integrating into the DNA of newly infected cells. Together with PhenoSense GT(R), PhenoSense Integrase provides the most complete picture of resistance to antiretroviral therapies.
PhenoSense Integrase along with other Monogram assays were used to support the clinical trials of the first commercially-available integrase inhibitor, Merck's Isentress(TM) (raltegravir), which received U.S. Food and Drug Administration (FDA) approval in October 2007. In Merck's phase III BENCHMRK trials, Monogram's PhenoSenseGT was used to select optimized drug regimens in the placebo and Isentress-containing treatment arms while PhenoSense Integrase was used to identify and characterize Isentress resistant viruses in treatment failures. The company is also actively involved in the clinical evaluation of Gilead's integrase inhibitor candidate, elvitegravir, currently in Phase III studies. In addition to drug resistance, PhenoSense Integrase also measures reductions in viral replication capacity associated with integrase inhibitor resistance that may help characterize viral fitness.
"Using new antiretroviral drugs correctly today, including HIV
integrase inhibitors, is critically important since the pipeline for
'/>"/>
| SOURCE Monogram Biosciences, Inc. Copyright©2008 PR Newswire. All rights reserved |